COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis
JW Senefeld, M Franchini, C Mengoli… - JAMA Network …, 2023 - jamanetwork.com
Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …
mortality associated with coronavirus disease 2019 (COVID-19) because they less …
COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes
D Focosi, M Franchini, L Pirofski… - Clinical microbiology …, 2022 - Am Soc Microbiol
Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …
available as soon as there are survivors. The COVID-19 pandemic represented the first …
[HTML][HTML] Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-COV-2 infection: defining a treatment pathway
A D'Abramo, S Vita, G Maffongelli… - Frontiers in …, 2022 - frontiersin.org
Introduction Immunocompromised patients with B-cell depletion agents are at risk for
persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID …
persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID …
Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review
MM Rezaei Tolzali, M Noori, P Shokri… - Reviews in Medical …, 2022 - Wiley Online Library
Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …
Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks
M Dhawan, M Parmar, S Angural… - International Journal of …, 2022 - journals.lww.com
Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) has resulted in a catastrophic pandemic and …
syndrome coronavirus-2 (SARS-CoV-2) has resulted in a catastrophic pandemic and …
[HTML][HTML] The unmet need for COVID-19 treatment in immunocompromised patients
A D'Abramo, S Vita, E Nicastri - BMC Infectious Diseases, 2022 - Springer
Background Immunocompromised (IC) patients are at increased risk of severe and/or
prolonged COVID-19. Main text The recent study by Scaglione et al., addresses the issue of …
prolonged COVID-19. Main text The recent study by Scaglione et al., addresses the issue of …
[HTML][HTML] COVID-19: variants, immunity, and therapeutics for non-hospitalized patients
CYS Lee, JB Suzuki - Biomedicines, 2023 - mdpi.com
The continuing transmission of coronavirus disease 2019 (COVID-19) remains a world-wide
21st-century public health emergency of concern. Severe acute respiratory syndrome …
21st-century public health emergency of concern. Severe acute respiratory syndrome …
[HTML][HTML] Monoclonal antibodies for pre-and postexposure prophylaxis of COVID-19: review of the literature
S Vita, S Rosati, T Ascoli Bartoli, A Beccacece… - Pathogens, 2022 - mdpi.com
Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability
to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory …
to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory …
[HTML][HTML] Hyperimmune Plasma and Immunoglobulins against COVID-19: a narrative review
M Franchini, D Focosi - Life, 2024 - mdpi.com
Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …
Vax-plasma in patients with refractory COVID-19
To the Editor: Convalescent plasma (CP) therapy uses neutralizing antibodies harvested
from recovered patients to treat viral infections, including severe acute respiratory syndrome …
from recovered patients to treat viral infections, including severe acute respiratory syndrome …